Citius Pharmaceuticals, Inc. (CTXR)
- Previous Close
0.6876 - Open
0.6750 - Bid 0.6438 x 800
- Ask 0.6563 x 800
- Day's Range
0.6499 - 0.6775 - 52 Week Range
0.6000 - 1.4000 - Volume
944,657 - Avg. Volume
956,781 - Market Cap (intraday)
118.654M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2600 - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.00
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
citiuspharma.comRecent News: CTXR
Performance Overview: CTXR
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CTXR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CTXR
Valuation Measures
Market Cap
124.13M
Enterprise Value
104.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.46
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.08%
Return on Equity (ttm)
-42.15%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-37.35M
Diluted EPS (ttm)
-0.2600
Balance Sheet and Cash Flow
Total Cash (mrq)
12.56M
Total Debt/Equity (mrq)
0.47%
Levered Free Cash Flow (ttm)
-18.99M
Research Analysis: CTXR
Company Insights: CTXR
CTXR does not have Company Insights